Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

GT Biopharma, Inc. (GTBP)

1.83   0.06 (3.39%) 11-25 13:00
Open: 1.8 Pre. Close: 1.77
High: 1.83 Low: 1.75
Volume: 5,035 Market Cap: 60(M)

Technical analysis

as of: 2022-11-28 8:48:42 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.31     One year: 2.68
Support: Support1: 1.46    Support2: 1.21
Resistance: Resistance1: 1.97    Resistance2: 2.29
Pivot: 2
Moving Average: MA(5): 1.85     MA(20): 1.98
MA(100): 2.26     MA(250): 2.6
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 9.4     %D(3): 10.5
RSI: RSI(14): 44.4
52-week: High: 3.89  Low: 1.46
Average Vol(K): 3-Month: 74 (K)  10-Days: 28 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GTBP ] has closed above bottom band by 15.0%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.83 - 1.84 1.84 - 1.85
Low: 1.72 - 1.74 1.74 - 1.75
Close: 1.81 - 1.83 1.83 - 1.85

Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Headline News

Thu, 10 Nov 2022
2022-11-10 | NDAQ:GTBP | Press Release | GT Biopharma Inc. - Stockhouse

Mon, 31 Oct 2022
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update - GlobeNewswire

Thu, 06 Oct 2022
GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting - Yahoo Finance

Wed, 21 Sep 2022
We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully - Simply Wall St

Tue, 30 Aug 2022
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 - Yahoo Finance

Wed, 08 Dec 2021
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 33 (M)
Shares Float 26 (M)
% Held by Insiders 15.1 (%)
% Held by Institutions 7.7 (%)
Shares Short 437 (K)
Shares Short P.Month 568 (K)

Stock Financials

EPS -1.05
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.49
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -74
Return on Equity (ttm) -139.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -15 (M)
Levered Free Cash Flow 3 (M)

Stock Valuations

PE Ratio -1.75
PEG Ratio 0
Price to Book value 3.73
Price to Sales 0
Price to Cash Flow -4.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-08-20
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.